Clinical-stage biopharmaceutical company DBV Technologies (NASDAQ:DBVT) announced a financing of up to $306.9M (€284.5M), including gross proceeds of $125.5M (€116.3M) to be received upon ...

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other ...

DBVT stock opened at $6.50 on Monday. The stock’s 50 day moving average is $4.70 and its two-hundred day moving average is $3.97. DBV Technologies has a 52-week low of $2.20 and a 52-week high ...